Profile data is unavailable for this security.
About the company
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations. The Company is mainly engaged in three businesses. The contract development and manufacturing organization (CDMO) business mainly provides pharmaceutical companies with CDMO services for the entire preparation industry chain. The specialty API business is mainly engaged in the production and sales of APIs. The preparation business is mainly engaged in the production and sales of preparations. The Company's main products include valsartan, losartan, perindopril, rosuvastatin calcium, atorvastatin calcium and pregabalin. The Company's products are mainly used in cardiovascular, central nervous, antiviral, hypoglycemic, gastrointestinal and other therapeutic areas. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in CNY (TTM)1.24bn
- Net income in CNY20.30m
- Incorporated2004
- Employees2.35k
- LocationNingbo Menovo Pharmaceutical Co LtdRoom 1406NINGBO 315048ChinaCHN
- Phone+86 57 487916065
- Fax+86 57 487918601
- Websitehttp://www.menovopharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Lianhuan Pharmaceutical Co. Ltd | 2.34bn | 138.87m | 2.71bn | 1.30k | 19.51 | 1.93 | -- | 1.16 | 0.4865 | 0.4865 | 8.18 | 4.92 | 0.8003 | 3.34 | 4.76 | 1,801,909.00 | 5.42 | 5.93 | 11.26 | 11.25 | 49.14 | 53.26 | 6.78 | 7.82 | 0.7061 | 6.61 | 0.3593 | 30.64 | 11.20 | 16.36 | -4.50 | 12.91 | 9.35 | 13.97 |
| Frontier Biotechnologies Inc | 122.86m | -316.34m | 2.72bn | 395.00 | -- | 2.30 | -- | 22.16 | -0.8445 | -0.8445 | 0.328 | 3.16 | 0.057 | 1.43 | 2.91 | 311,049.00 | -14.67 | -14.05 | -17.86 | -15.78 | 31.82 | 2.35 | -257.47 | -450.08 | 2.11 | -- | 0.2763 | -- | 34.82 | 126.63 | 7.79 | -- | 28.13 | -- |
| Ningbo Menovo Pharmaceutical Co Ltd | 1.24bn | 20.30m | 2.92bn | 2.35k | 153.22 | 1.34 | -- | 2.36 | 0.087 | 0.087 | 5.70 | 9.92 | 0.267 | 1.18 | 4.91 | 525,730.80 | 0.5164 | 4.94 | 0.7951 | 7.83 | 29.01 | 35.39 | 1.93 | 13.71 | 0.7203 | 4.44 | 0.4199 | 10.78 | -16.51 | 7.46 | -96.58 | -34.53 | -6.03 | -32.54 |
| Henan Taloph Pharmaceutical Stock Co Ltd | 1.97bn | 89.38m | 2.94bn | 2.35k | 33.87 | 1.87 | -- | 1.50 | 0.1515 | 0.1515 | 3.39 | 2.74 | 0.5571 | 2.93 | 2.06 | 836,256.80 | 2.67 | 0.272 | 5.80 | 0.4981 | 27.64 | 27.97 | 4.79 | 0.5501 | 0.8146 | 2.65 | 0.3911 | 28.70 | 5.57 | 11.62 | 160.32 | -- | -8.27 | -- |
| GuiZhou YiBai Pharmaceutical Co., Ltd. | 2.40bn | -235.62m | 2.95bn | 5.51k | -- | 1.12 | -- | 1.23 | -0.2975 | -0.2975 | 3.03 | 3.34 | 0.5288 | 1.52 | 13.04 | 435,209.10 | -5.39 | 0.8648 | -6.97 | 1.18 | 61.81 | 74.87 | -10.19 | 1.45 | 1.36 | -9.98 | 0.2375 | 216.36 | 3.12 | -6.19 | 124.25 | -- | -16.51 | -- |
| Shanghai MicuRx Pharmaceutical Co Ltd | 120.07m | -467.96m | 3.11bn | 205.00 | -- | 5.48 | -- | 25.92 | -0.7142 | -0.7142 | 0.1833 | 0.8664 | 0.1067 | 0.623 | 4.76 | 585,689.70 | -41.57 | -- | -45.49 | -- | 81.88 | -- | -389.75 | -- | 6.43 | -- | 0.3488 | -- | 88.31 | -- | -91.16 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2024 | 6.26m | 2.95% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 831.31k | 0.39% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 412.00k | 0.19% |
| Gfund Management Co., Ltd.as of 30 Jun 2024 | 141.90k | 0.07% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 65.90k | 0.03% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 48.60k | 0.02% |
| Founder Fubon Fund Management Co., Ltd.as of 30 Jun 2024 | 32.60k | 0.02% |
| Everbright PGIM Fund Management Co. Ltd.as of 30 Jun 2024 | 30.79k | 0.02% |
| JPMorgan Asset Management (China) Co Ltd.as of 30 Jun 2024 | 15.93k | 0.01% |
| Fortune & Royal Asset Management Co., Ltd.as of 30 Jun 2024 | 15.80k | 0.01% |
